Teri Willey
InvestorP2C Managing Director & Officer at Pathway to Cures
Bloomington, Indiana, United States
About
Willey joined NBDF in November 2022 to launch and lead Pathway to Cures. She has over 35 years of experience commercializing early-stage research, previously serving as founding managing director of IU Ventures' Indiana Philanthropic Venture Fund, founding chief executive of Cambridge Enterprise Ltd, and co-founder of ARCH Development Partners.
Experience
- Pathway to CuresInvestment Advisorcurrent2026 — presentNew York, New York, United States
- Pathway to CuresFounding Managing Director and Officer2022 — 2026New York, United States
- Pathway to CuresAdvisor to the National Bleeding Disorders Foundation2022New York, United States
- Royalty PharmaAdvisorcurrent2023 — presentNew York, United States
- Sealth Biotherapeutics CompanyNon-Executive Chair, Board of Directorscurrent2026 — present
- Sixty8 CapitalLimited Partnercurrent2021 — presentIndiana, United States
- PortfoliaInvesting Member - Rising America I, II and III Fund and FemTech II Fundcurrent2020 — present
- Spin-outs DenmarkAdvisory Board Membercurrent2021 — presentCopenhagen, Capital Region of Denmark, Denmark
- Lake Monroe Water FundBoard of Directorscurrent2023 — presentBloomington, Indiana, United States
- Cold Spring Harbor LaboratoryBusiness Development Advisorcurrent2020 — presentCold Spring Harbor, New York, United States
- Oncode InstituteInternational Advisory Board, Chair2018 — 2026The Randstad, Netherlands
- Spark Biomedical IncBoard Observer - FiveLiters a Pathway to Cures portfolio company2023 — 2024Dallas, Texas, United States
- Indiana University FoundationFounding Member, Black Philanthropy Circle2020 — 2024Bloomington, Indiana, United States
- IU VenturesAdvisor2022 — 2023
- IU VenturesManaging Director2018 — 2022Greater Bloomington Area
- Kovina TherapeuticsNon Executive Director2021 — 2022Indianapolis, Indiana, United States
- Diagnotes, Inc.Non Executive Director2019 — 2022Indianapolis, Indiana
- PeriodicNon Executive Director2019 — 2022Greater Bloomington Area
- The MillInvesting Member - Flywheel Fund I2020 — 2021Bloomington, Indiana, United States
- Cold Spring Harbor LaboratoryBusiness Development Advisor2018Cold Spring Harbor, New York
- Cold Spring Harbor LaboratoryVice President for Business Development & Technology Transfer2013 — 2018Cold Spring Harbor, New York
- Stoke TherapeuticsBoard Observer2015 — 2018Boston, Massachusetts, United States
- AUTMDirector2014 — 2016
- Mount SinaiVice President, The Mount Sinai Medical Center, Technology and Business Development2011 — 2013New York City
- Cambridge Enterprise, LtdDirector (NED)2011 — 2012Greater Cambridge Area
- Cambridge Enterprise, LtdFounding Chief Executive and Executive Director2006 — 2011Greater Cambridge Area
- ARCH Development Partners, LLCManaging Partner and Co-Founder2001 — 2008Chicago, IL
- University of Notre DameAdjuct Faculty2001 — 2005
- University of ChicagoVice President - ARCH Development Corporation1997 — 2001Chicago, IL
- Purdue Research FoundationDirector1991 — 1997
- AUTMPresident1996 — 1997
- Corporation for Science and TechnologyProject Manager1989 — 1991Indianapolis, Indiana
- Northwestern UniversityAssistant Director1985 — 1989Evanston, Illinois
- International Minerals and ChemicalManager1981 — 1985
Skills & more
Management16Strategy17Entrepreneurship58Biotechnology45Start-ups54Technology Transfer83Lifesciences51Innovation Management12Research18Intellectual Property20Licensing25Commercialization65
+12 more
Business DevelopmentProduct DevelopmentGenomicsDrug DiscoveryVenture CapitalHealthcareR&DBiochemistryMolecular BiologyInvestmentsPharmaceutical IndustryMedical DevicesFrom Teri's professional profile.
Colleagues at Pathway to Cures
Amy L. Dunn
Chair, Medical and Scientific Advisory Council (MASAC) for NBDF at Pathway to Cures
Beth Whitehouse
NBDF Senior Vice President for Advancement at Pathway to Cures
Brian Andrew
Investment Committee Chair at Pathway to Cures
Christine Brennan
Investment Committee Member at Pathway to Cures
Geeta Vemuri
Managing Partner, Founder at Agent Capital
Gilbert C. White
P2C Board Vice Chair & Secretary at Pathway to Cures
Gilbert C. White, II
P2C Board Vice Chair & Secretary at Pathway to Cures
Glenn Pierce
Scientific Advisory Group Co-Chair at Pathway to Cures
Frequently asked questions
- Who is Teri Willey?
- Willey joined NBDF in November 2022 to launch and lead Pathway to Cures. She has over 35 years of experience commercializing early-stage research, previously serving as founding managing director of IU Ventures' Indiana Philanthropic Venture Fund, founding chief executive of Cambridge Enterprise Ltd, and co-founder of ARCH Development Partners.
- Where does Teri Willey work?
- Teri Willey is P2C Managing Director & Officer at Pathway to Cures.
- Where did Teri Willey go to school?
- Teri Willey studied at Indiana State University (Masters Business Administration, Finance); University of Idaho (Bachelor's degree, Animal Sciences); Pocatello High School, Idaho.
Same school
Also attended Indiana State University5
Also attended University of Idaho9
Julia HitchinsInvestor at Positive Sum CapitalBen GreenfieldInvestor at Seaside VenturesJohn RockwellVenture Partner at Tramway Venture PartnersBryan ClarkAdvisor at Marlinspike PartnersUmesh LimayeInvestor at Micron VenturesCharla TriplettAdvisor at Suncoast Ventures
+ 3 more
Shared employers
Also worked at Cold Spring Harbor Laboratory13
Zach CollinsPartner at Mission BiocapitalUkjin (Jay) KwonPrincipal at SazzeSophia MichaelsAssociate at CVS Health VenturesAvidan RudanskyInvestor at Maccabee VenturesThomas D. LehrmanManaging Partner at Teamworthy VenturesMichael GutbrodSenior Associate at Sante Ventures
+ 7 more
Also worked at Oncode Institute6
René KuijtenInvestor at LSP (Life Sciences Partners)René R. KuijtenInvestor at LSP (Life Sciences Partners)René KuijtenPartner, Head of EQT Life Sciences at EQT Life SciencesRudy DekeyserPartner, Head of Health Economic Funds at EQT Life SciencesMarkwin VeldersAdvisory Committee member at Curie CapitalJanine SchuurmanSenior Advisor at Bioqube Ventures
